leisure time -WSS

leisure time

author：comprehensive 2025-09-06 02:05:59 - browse：4

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： New air purifier tech could be key to improving indoor air quality

entertainment

WSS

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

HHS secretary Becerra pressed on Change HealthCare cyberattack

BioMarin wins approval for gene therapy to treat hemophilia A

After affirmative action ruling, medical educators look to 'holistic review'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In Memoriam: Notable people who died in 2023

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hollywood unions extend contract negotiations for actors

Why depression after traumatic brain injury is distinct

As demand for Covid shots wanes, Moderna seeks its next success

In age of alternative facts, a scholarly course on calling out crap

Hepatitis C has a cure — but many Americans still lack access to it

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Sports medicine is finally prioritizing gender equality

WuXi out of biotech trade group, U.S. and China relations to blame

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Dobbs anniversary: the lost opportunity of abortion as health care

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Novavax promises a turnaround & Lilly roils the obesity market

How to save health care price transparency rules

entertainment

hotspot

knowledge

knowledge